Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX

Kiora Pharmaceuticals — Eyegate Pharmaceuticals — Investor Presentation (February 2018)

14 slides from Kiora Pharmaceuticals's investor presentation, Feb 26, 2018

  1. Slide 1: EyeGate Pharmaceuticals, Inc. - OBG: The Ocular Liquid Bandage

    www.eyegatepharma.com NASDAQ: EYEG NASDAQ: EYEG EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com OBG: The Ocular Liquid Bandage A crosslinked hyaluronic acid (CMHA - S) eye drop for corneal wounds and epitheliopathies, including dry eye Follow u

  2. Slide 2: Forward Looking Statements

    www.eyegatepharma.com NASDAQ: EYEG Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements relating to the prospects for the Company’s lead product EGP - 437, for the ti

  3. Slide 3: Hyaluronic Acid Properties

    www.eyegatepharma.com NASDAQ: EYEG 3 Hyaluronic Acid Properties High - molecular weight HA is non - immunogenic High - molecular weight HA binds up to 1,000 times its volume in water weight HA provides: hydration, lubrication of joints, and a meshwork for cell migration Regulatory Approvals U.S. – D

  4. Slide 4: First and Only Eye Drop in the U.S. Targeting Acceleration of Re-Epithelialization

    www.eyegatepharma.com NASDAQ: EYEG First and Only Eye Drop in the U.S. Targeting Acceleration of Re - Epithelialization 4 EyeGate’s CMHA - S Platform: A unique crosslinked, high concentration version of Hyaluronic acid ▪ Crosslinking creates a 3D structure that stabilizes the molecule  R esists deg

  5. Slide 5: Demonstrated efficacy and safety in animals

    www.eyegatepharma.com NASDAQ: EYEG Commercially available as a veterinary device ▪ Manufactured by SentrX Animal Care ▪ Sold in the U.S. and certain European countries by Bayer Animal Health as Remend® Corneal Repair 1 ▪ 5 years in thousands of dogs, cats and horses, with an excellent efficacy/safet

  6. Slide 6: Healing Corneal Abrasions and Alkali Burns Efficacy Study: Rabbits

    www.eyegatepharma.com NASDAQ: EYEG CMHA - S treated cornea exhibited “more normal” epithelial and stromal organization 6 Healing Corneal Abrasions and Alkali Burns Efficacy Study: Rabbits 1 1. Guanghui Yang, Ladan Espandar, Nick Mamalis and Glenn D. Prestwich, Veterinary Ophthalmology 2010 Histology

  7. Slide 7: Completed First Human Clinical Trial in PRK Patients

    www.eyegatepharma.com NASDAQ: EYEG Completed First Human Clinical Trial in PRK Patients 7 x PRK surgery provides several advantages as indication to evaluate the Ocular Liquid Bandage Gel (OBG) ▪ A homogenous patient population with large epithelial defects of the same size x 39 subjects randomized

  8. Slide 8: Meeting with FDA Confirms de novo 510(k) Filing Path

    www.eyegatepharma.com NASDAQ: EYEG Meeting with FDA (Nov 2016) Confirms de novo 510(k) Filing Path 8 Eye Drop Regulated as a Device Accelerates Development Plan Initial Two Indications: Photorefractive Keratectomy and Punctate Epitheliopathies ▪ No predicate device – label determined by clinical tri

  9. Slide 9: Management of Punctate Epitheliopathy Pilot Trial Design

    www.eyegatepharma.com NASDAQ: EYEG 9 Management of Punctate Epitheliopathy Pilot Trial Design ▪ PE as defined by fluorescein staining of cornea: NEI scale • Randomization: NEI score ≥ 5 ▪ 30 subjects for 2 arm trial: 15 subjects per arm • Safety will include both eyes (N = 60) ▪ 42 Day trial: 2 week

  10. Slide 10: Broad Clinical Application & Large Market Opportunity

    www.eyegatepharma.com NASDAQ: EYEG ▪ Corneal foreign bodies ▪ Abrasions / contusions ▪ Chemical burns ▪ Difficult to heal alkali burns (PCED) EyeGate Ocular Bandage Gel (OBG) Broad Clinical Application & Large Market Opportunity 10 ▪ Refractive surgeries (PRK) ▪ Vitrectomies (Diabetics) ▪ Collagen c

  11. Slide 11: Continued Unmet Medical Need & Modest Development Investment Creates Opportunity

    www.eyegatepharma.com NASDAQ: EYEG Over 76M patients with corneal wounds or epitheliopathies in US but only 3.5M Rx’s of current treatment options Continued Unmet Medical Need & Modest Development Investment Creates Opportunity Even in Face of Generic Restasis Entry 11 • Primary focus on punctate ep

  12. Slide 12: Development Timeline

    www.eyegatepharma.com NASDAQ: EYEG Development Timeline Program Disease Area 2017 2018 2019 2020 Large Corneal Wounds Photorefractive Keratectomy (PRK) Punctate Epitheliopathies Focus: Moderate Dry Eye OBG + Corticosteroid Eye Drop Crosslinked Hyaluronic Acid Punctate Epitheliopathies Focus: Severe

  13. Slide 13: A New Product: Improves Upon an Old Standby

    www.eyegatepharma.com NASDAQ: EYEG Proprietary Formulation of HA Resists Degradation and Accelerates Re - Epithelialization A New Product: Improves Upon an Old Standby 13 • Proprietary crosslinked HA produces a preservative - free, high concentration eyedrop that resists degradation and adheres to t

  14. Slide 14: Thank You!

    www.eyegatepharma.com NASDAQ: EYEG EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Thank You! NASDAQ: EYEG www.eyegatepharma.com Follow us on Facebook, LinkedIn and Twitter

Eyegate Pharmaceuticals — Investor Presentation (February 2018) on 6ix